Also, SGLT2 inhibitors were superior to glucagon-like peptide-1 (GLP-1) receptor agonists in reducing hospitalization for heart failure (HHF) and a composite kidney outcome (Davies et al., 2022). This evidence concerns the gene SLC5A2 and heart failure.